IXICO PLC (LON:IXI), the pioneer of digital technologies used in neuroscience, has landed a two-year contract worth £500,000 with a top-15 pharma company to deploy its wrist-worn sensors in a Phase II clinical trial.
It is the company’s first commercial agreement using the devices. They will be used along with artificial intelligence data analytics algorithms to monitor sleep disturbance in around 300 people.
READ: IXICO signs new contract, worth US$690,000 for its technology enabled imaging services
“The work performed in this clinical trial, represents an important step in the validation of biosensors as new digital technologies in a specific context of use, as required by regulatory authorities,” IXICO said in a statement.
Chief executive Giulio Cerroni added: “This is an excellent opportunity for IXICO to demonstrate how our biosensor services and technology, build upon our well-established expertise in providing regulatory compliant imaging endpoints in clinical trials, to support the process of developing new drugs to treat neurological diseases.”